Home » Topics » Disease categories and therapies » Neurology/psychiatric

Neurology/psychiatric
RSS

Positive phase I results reported for TCAR product for MS

Feb. 24, 1998

CPMP recommends European approval of Exelon

Feb. 24, 1998

Muscarinic cholinergic agents from American Home

Feb. 24, 1998

Neurocrine Biosciences reveals new technology

Feb. 24, 1998

Evaluation of the analgesic potential of 1,2,6-IP3

Feb. 24, 1998

Excellent anxiolytic/side effect profile described for LY-354740

Feb. 23, 1998

Reduction in brain damage with YM-872 in cat model of focal cerebral ischemia

Feb. 23, 1998

Ganaxolone demonstrates efficacy in phase II migraine trial

Feb. 23, 1998

Novel NK1 antagonists described by Merck & Co.

Feb. 23, 1998

Antidepressant properties of flibanserin may involve dopamine D2/D3 receptors

Feb. 23, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 8, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Italy’s Angelini pays $4.1B cash for rare disease specialist Catalyst
BioWorld
Italian family-owned Angelini Pharma SpA is making its first move into the U.S. market, acquiring rare diseases specialist Catalyst Pharma Inc. in an all-cash...